Current status and outlook of medical treatment for KRAS-mutated non-small cell lung cancer.
10.3760/cma.j.cn112152-20220310-00167
- Author:
Wei XU
1
;
Xiao Li ZHUO
1
;
Lei LIU
1
;
Jing ZHAO
1
;
Xiao Yan LIN
2
;
Guo Bin FU
1
Author Information
1. Department of Oncology, Shandong Provincial Hospital, Shandong University, Jinan 250021, China.
2. Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.
- Publication Type:Journal Article
- Keywords:
Carcinoma, non-small-cell lung;
Kirsten rat sarcoma viral oncogene homolog;
Target therapy
- MeSH:
Male;
Humans;
Female;
Carcinoma, Non-Small-Cell Lung/pathology*;
Lung Neoplasms/genetics*;
Proto-Oncogene Proteins p21(ras)/therapeutic use*;
Genes, ras;
Immune Checkpoint Inhibitors/therapeutic use*;
Guanosine Triphosphate/therapeutic use*;
Mutation
- From:
Chinese Journal of Oncology
2023;45(2):111-116
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer remains the leading cause of cancer-related deaths in men and women worldwide, and 85% of these patients have non-small cell lung cancer. In recent years, the clinical use of targeted drug therapy and immune checkpoint inhibitors has dramatically changed the treatment landscape for advanced NSCLC. The mechanism and the value of targeted therapies have been a hot topic of research, as KRAS is one of the earliest discovered and most frequently mutated oncogenes, which is activated by binding to GTP and triggers a series of cascade reactions in cell proliferation and mitosis. The KRAS protein acts as a molecular switch and is activated by binding to GTP, triggering a series of cascade responses in cell proliferation and mitosis. Clinically, patients with KRAS mutated NSCLC have poor response to systemic medical therapy and poor prognosis. Since the first report of KRAS gene in 1982, research on KRAS targeted therapeutics has been slow, and previous studies such as farnesyltransferase inhibitors and downstream protein inhibitors of KRAS signaling pathway have not achieved the expected results, making KRAS long defined as a "non-druggable target". The deeper understanding of the crystal structure of KRAS has led to the discovery of potential therapeutic sites for KRAS and the development of several drugs directly targeting KRAS, especially KRAS G12C inhibitors such as AMG510 (sotorasib) and MRTX849 (adagrasib), which have shown encouraging results in clinical trials. In recent years, studies on the therapeutic efficacy of immune checkpoint inhibitors for KRAS-mutated NSCLC have made some progress. In this review, we systematically introduce the basic understanding of RAS gene and clinical characteristics of KRAS mutated NSCLC patients, summarize the medical treatments for KRAS mutated NSCLC, including chemotherapy, anti-vascular drug therapy and tumor immunotherapy, and focus on the review and outlook of the research progress of KRAS targeted therapy.
